Chief Development Officer (CDO) Grethe Nørskov Rasmussen sells shares

About FluoGuide
FluoGuide takes precision surgery to the next level improving the outcome for cancer patients.
The Company’s lead product, FG001, is designed to improve surgical precision by illuminating
cancer intraoperatively. This improved precision enabled by FluoGuide’s products is expected to
have a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens
surgical sequelae. Ultimately, this improved precision will improve a patient’s chance of achieving
a complete cure and will lower system-wide healthcare costs.

The Company has published key results on the efficacy of FG001 as well as showing it was well
tolerated and safe from clinical trials in patients with aggressive brain cancer (high-grade glioma)
that undergo surgery. In addition, FluoGuide has demonstrated the effect of FG001 in lung and
head & neck cancers.

For more information on the Company, please visit www.fluoguide.com.